The DIRECTOR slides
are faster, more precise and accurate than any other microdissection
technology. They dramatically simplify
collection of tissue features from all kinds of tissue, and
are well suited for both genomic and proteomic applications.
The DIRECTOR slides are fully compatible with both the Leica
LMD and the P.A.L.M. Zeiss laser microdissection platforms.
In our own laboratories we use a Leica LMD6000 system
from Leica Microsystems.
Principles of Fast Forward Microdissection
The tissue is mounted on top of a thin energy transfer
coating. When the laser is pulsed, the energy coating is
vaporized and the tissue is instantly propelled into the
cap. Download 3Mb .wmv file of the streaming video below.
Actual microdissection of a prostate cancer section from a DIRECTOR
slide (20X magnification) on a Leica LMD6000 system. Regions
are marked and collected using the scanning/raster function
of the most
recent LMD6000
software.
The
different colors are collected in different caps. Regions can
be marked up all over the slide, also outside of the immediate
field of vision. The videos
were recorded in our laboratories using a Leica LMD6000 laser
microdissector,
and SnagIt.
Clip 1. Download a 14 mb .wmv file of the video above here: Draw
and Scan Mode
-
Clip 2. Download a 6 Mb .wmv file here: Move
and Cut Mode - Tissue is cut continuously as the cursor
is moved. Excellent for collecting e.g. cancerous epithelium.
Clip 3. Download a 3 Mb file here: Draw
then cut - For when multiple thin regions
need to be marked up and collected.
These video files are downsampled from the original high-resolution
files.
The software
tracks
the total area
collected.
This makes it easy
to estimate how much tissue has been collected.
For more information regarding the Leica LMD6000
microdissector, please
contact your
local Leica
Microsystems representative.
Expression
Pathology Inc. (EPI) is a leader in tissue
microproteomics. Our technologies make possible
mass spec protein analysis of formalin-fixed
tissue, enabling discovery, validation and routine
measurement of protein biomarkers related
to clinical outcomes. Our near-term mission
is to offer breakthrough research tools and
collaborations to improve drug and diagnostic
development and for basic research. Our proprietary
technologies also provide the foundation
for a whole new platform of tissue diagnostic
tests currently under development.
The Liquid
Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures the entire
protein content. Mass spec friendly. Requires only 30,000 cells for
multiple mass spectrometry analyses.
The Director™ Laser Microdissection
Slides provide the fastest, easiest and most accurate way to collect
specific cellular features from tissue sections. Engineered for
use with existing Leica LMD and PALM Zeiss laser microdissection
system.
news sidebar
News & Events
NextGen
Sciences and Expression Pathology to provide protein biomarker
discovery and measurement in tissue, June 30, 2008. (press
release)
Quantitative
Proteomic Analysis of Formalin Fixed Paraffin Embedded Oral HPV Lesions
from HIV Patients, The Open Proteomics Journal, 2008, 1, 40-45,
June 15, 2008. (abstract)
Two
of Expression Pathology's key patents have issued covering
its DIRECTOR™ Slide technology for improved tissue laser microdissection Gaithersburg,
MD. May 19, 2008: (press release).
Expression
Pathology Obtains SBIR to Identify Protein Biomarkers of Breast
Cancer
Metastasis, May 15, 2008 (press
release).
ASMS,
Denver, June 1-5. (link)
Booth 21. Register for our tissue proteomic luncheon
seminar on Wednesday, June 4.
American
Association of Cancer Research, San
Diego, April 12-16. (link)
Booth 2428. See three posters using our technology; discovery
of endometrial cancer markers (write-up),
metastasis marker in melanoma (abstract),
protein biomarkers relating to metastasis and disease progression
in lung cancer (abstract).
A Molecular Portrait of Head and Neck Cancer Progression,
Clin. Cancer Res., Feb. 15, 2008 (abstract)
Expression Pathology Aids Research in Identifying Biomarkers
of Lung Cancer Metastasis and Survival, Feb. 19, 2008 (article
and press release)
Expression Pathology Obtains Maryland Funding to Develop
Breast Cancer Test, Feb. 6, 2008(press
release)
